ArticleeLife2014
Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility.
Article in eLife, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.The Journal of clinical investigation · 2017Trial
- Psoriasis-like disease prevents squamous skin tumor development by neutrophil-driven inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Loss of the translational repressor 4E-BP1 promotes skin carcinogenesis.Frontiers in pharmacology · 2026Article
- Caspase-8-dependent autophagy regulates neutrophil infiltration in oral squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis.Cancers · 2023Article
- The Anti-Tumorigenic Role of Cannabinoid Receptor 2 in Non-Melanoma Skin Cancer.International journal of molecular sciences · 2023Article
- An integrative analysis of enhancer of yellow 2 homolog (ENY2) as a molecular biomarker in pan-cancer.Functional & integrative genomics · 2023Article
- Embigin is a fibronectin receptor that affects sebaceous gland differentiation and metabolism.Developmental cell · 2022Article
- Innate lymphoid cells in early tumor development.Frontiers in immunology · 2022Review
- Identification of Biomarkers Associated With CD4Frontiers in immunology · 2022Article
- Article
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence.Cell communication and signaling : CCS · 2021Review
- IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases?Antibodies (Basel, Switzerland) · 2020Review
- Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis.Oncogene · 2020Article
- Molecular Nanomachines Can Destroy Tissue or Kill Multicellular Eukaryotes.ACS applied materials & interfaces · 2020Article
- Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms.Frontiers in immunology · 2020Review
- Cell Type-Specific p38δ Targeting Reveals a Context-, Stage-, and Sex-Dependent Regulation of Skin Carcinogenesis.International journal of molecular sciences · 2019Article
- Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.The Journal of investigative dermatology · 2019Article
- Challenging Treatment of Ocular Surface Squamous Neoplasia in Patients with Atopic Disease.Ocular immunology and inflammation · 2019Article
- Cdc42 Deficiency Leads To Epidermal Barrier Dysfunction by Regulating Intercellular Junctions and Keratinization of Epidermal Cells during Mouse Skin Development.Theranostics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI-/- mice, which lack three barrier proteins-Envoplakin, Periplakin, and Involucrin. EPI-/- mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI-/- skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2D but not CD4+ T cells. We conclude that atopy is protective against skin cancer in our experimental model and that the mechanism involves keratinocytes communicating with cells of the immune system via signalling elements that normally protect against environmental assaults.DOI: http://dx.doi.org/10.7554/eLife.01888.001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.